Kringle Pharma (4884) · InitiativeRestatedLatest Business Alliances (2026-09-16): "Advanced"
Hybrid business model combining in-house development, sales partnerships and active pharmaceutical ingredient supply
First written in FY2020. 1 of 3 entries say "Restated". Latest entry: 2026-09-16.
3entries
7years
1from disclosures
How it moved
Same theme, other companies
Hybrid Business Model Combining In-House Development, Sales Partnerships, and API SupplyA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-09-16AdvancedBusiness Alliances
「本契約の締結により、当社は本製品の開発・製造に経営資源を集中させるとともに、契約一時金、開発マイルストーン及び販売後ロイヤルティによる収益機会を確保し、事業基盤の強化を図ってまいります。」
声帯瘢痕治療薬について、自社が開発・製造を担い、販売提携先が販売・プロモーションを担う役割分担が契約締結段階へ進み、ハイブリッド型事業モデルが具体化した。 - FY2022RestatedAnnual report
「We seek to pursue a hybrid business model combining A, B and C according to the target disease and the partner.」
The company continues to pursue a business model combining in-house development, sales partnerships and active pharmaceutical ingredient supply according to the target disease and partner. - FY2020First statedAnnual report
「We seek to pursue a hybrid business model combining A, B and C according to the target disease and the partner.」
The company seeks to combine in-house development, sales partnerships and active pharmaceutical ingredient supply according to the target disease and partner.